Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | 9-ING-41 + Doxorubicin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
9-ING-41 | 9 ING 41 | GSK-3beta Inhibitor 4 | 9-ING-41 is an ATP-competitive inhibitor that selectively blocks GSK-3beta, potentially leading to cell cycle arrest and apoptosis, and antitumor effects including inhibition of cell proliferation and tumor growth (PMID: 31894292, PMID: 29846250). | |
Doxorubicin | Adriamycin | Adria|ADR|Doxorubicin hydrochloride|Hydroxydaunorubicin | Chemotherapy - Anthracycline 11 TOPO2 inhibitor 5 | Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03678883 | Phase Ib/II | 9-ING-41 + Carboplatin + Paclitaxel 9-ING-41 + Irinotecan 9-ING-41 + Doxorubicin 9-ING-41 + Lomustine 9-ING-41 + Carboplatin 9-ING-41 + Gemcitabine + Nab-paclitaxel 9-ING-41 9-ING-41 + Gemcitabine | 9-ING-41 in Patients With Advanced Cancers | Recruiting | USA | ESP | 1 |